Higher rate of endophthalmitis after 25-gauge PPV

Article

The rate of endophthalmitis after 25-gauge pars plana vitrectomy (PPV) is significantly higher than that after 20-gauge PPV.

The rate of endophthalmitis after 25-gauge pars plana vitrectomy (PPV) is significantly higher than that after 20-gauge PPV, according to the results of a study published in the January issue of Retina.

Ingrid Scott from the Bascom Palmer Eye Institute, Miami, USA and colleagues from other US ophthalmic centers conducted a computerized database search at each centre to identify all patients who had undergone PPV between January 1, 2005 and December 31, 2006, and who were subsequently treated for endophthalmitis. In addition, all patients who underwent PPV and were subsequently treated for endophthalmitis at Pennsylvania State College of Medicine and Bascom Palmer Eye Institute during the study period were included. The medical records of these patients were reviewed to confirm that the endophthalmitis was associated with PPV.

The incidence of endophthalmitis during the study period was two cases per 6,375 patients (0.03%) for 20-gauge PPV compared with 11 cases per 1,307 patients (0.84%) for 25-gauge PPV (p<0.0001). Of 11 eyes that developed endophthalmitis after 25-gauge PPV, nine received endophthalmitis prophylaxis with subconjunctival cefazolin after surgery. Cultures were negative in three cases and no culture specimens were obtained in one case. Six of the seven isolates were coagulase-negative staphylococci, and one was enterococcus. Five of six isolates tested for sensitivity to vancomycin were sensitive, and both isolates tested for sensitivity to ceftazidime were sensitive.

In addition to discovering that the rate of endophthalmitis after 25-gauge PPV is significantly higher than that after 20-gauge PPV, endophthalmitis after 25-gauge was usually due to coagulase-negative staphylococci sensitive to vancomycin, and was associated with variable visual outcomes.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.